APPROACH UNDER REVIEW: `prompt-only`

SCENARIO ID: scenario_11
APP DESCRIPTION: SkinTrack lets patients photograph their moles monthly and stores standardized images. No AI — the app just prompts the photo and shows past photos side-by-side. If size/color changes by more than a threshold, the app suggests booking a dermatologist appointment. EU market.

DEVELOPER PERSONA: Indie founder, dermatology-curious, single-person team.

EXPECTED HERA DIMENSIONS (gold standard): P1.D1, P1.D3, P1.D4, P1.D5, P2.D1, P2.D3, P4.D3, P4.D4, P5.D2, P6.D2, P7.D1

TRANSCRIPT:
### USER
SkinTrack lets patients photograph their moles monthly and stores standardized images. No AI — the app just prompts the photo and shows past photos side-by-side. If size/color changes by more than a threshold, the app suggests booking a dermatologist appointment. EU market.

### ASSISTANT
**HERA Dimension: [P2.D3] — Data Collection and Use**  
**Reflection Question:** *How does the app ensure that the data collected (i.e., mole images) is collected, stored, and used in a way that respects user privacy and complies with GDPR?*

**Concrete Risk:**  
The app collects sensitive personal health data (skin images), which is considered **special category data** under GDPR. If the data is not properly anonymized, encrypted, or pseudonymized, it could expose users to privacy risks.

**Regulatory Reference:**  
- **GDPR Article 9** (special category data)  
- **GDPR Article 30** (record of processing activities)  
- **GDPR Article 35** (data protection impact assessment for high-risk processing)

**Actionable Mitigation:**  
- Conduct a **Data Protection Impact Assessment (DPIA)** under GDPR Article 35 to evaluate risks associated with collecting and storing sensitive health data.  
- Implement **pseudonymization** or **anonymization** of the images where possible.  
- Ensure **encryption** of data at rest and in transit.  
- Obtain **explicit consent** for data collection and processing, and allow users to **opt out** or **delete** their data.  
- Maintain a **record of processing activities** under GDPR Article 30.

---

**HERA Dimension: [P4.D6] — Transparency and User Control**  
**Reflection Question:** *Does the app provide users with clear information about how their data is used, stored, and shared, and do they have control over their data?*

**Concrete Risk:**  
If users are not clearly informed about how their mole images are stored, who has access to them, and how they can delete their data, this could lead to a lack of trust and potential legal issues under GDPR.

**Regulatory Reference:**  
- **GDPR Article 13** (information to be provided to data subjects)  
- **GDPR Article 14** (data subject rights, including right to access and erasure)

**Actionable Mitigation:**  
- Provide a **clear privacy notice** explaining how data is used, stored, and shared.  
- Allow users to **access**, **correct**, **delete**, or **port** their data.  
- Include a **privacy policy** that is easy to understand and accessible.  
- Offer users the ability to **opt out** of data sharing or processing.  

---

**HERA Dimension: [P5.D1] — Security and Data Protection**  
**Reflection Question:** *What security measures are in place to protect the mole images and user data from unauthorized access, breaches, or misuse?*

**Concrete Risk:**  
The app stores user-generated mole images, which are sensitive and could be exploited if not properly secured. A breach could lead to serious consequences for users, including identity theft or misuse of health data.

**Regulatory Reference:**  
- **GDPR Article 32** (security of processing)  
- **GDPR Article 33** (notification of data breaches)  
- **EU AI Act, Article 5(2)** (data security requirements for high-risk systems)

**Actionable Mitigation:**  
- Implement **strong access controls** and **role-based permissions**.  
- Use **encryption** for data at rest and in transit.  
- Conduct **regular security audits** and penetration testing.  
- Have a **data breach response plan** in place, including notification procedures under GDPR Article 33.  
- Consider **ISO 27001** for information security management.  

---

**HERA Dimension: [P7.D4] — Ethical Use and Harm Prevention**  
**Reflection Question:** *Is the app designed to prevent harm, such as false reassurance or unnecessary medical appointments, and does it avoid creating undue anxiety in users?*

**Concrete Risk:**  
The app may lead to **false positives** (e.g., suggesting a dermatologist visit when there is no real risk), which could cause unnecessary anxiety or strain on healthcare systems. Conversely, **false negatives** (not detecting changes when they exist) could lead to delayed treatment.

**Regulatory Reference:**  
- **EU AI Act, Article 5(2)** (risk minimization)  
- **MDR (Medical Device Regulation), Article 10** (risk management)

**Actionable Mitigation:**  
- Ensure that the app’s **thresholds for suggesting a dermatologist visit** are based on **clinical guidelines** and validated through **clinical testing**.  
- Include **disclaimers** that the app is not a substitute for professional medical advice.  
- Provide **clear instructions** on how to interpret the app’s findings and when to seek professional help.  
- Consider **user feedback mechanisms** to refine the app’s accuracy over time.  

---

Would you like to explore any of these dimensions in more depth or address specific

### USER
Mole photos (with location, date), user-marked changes, optional symptom notes.

### ASSISTANT
Thank you for the additional details. Let’s now explore how these **additional data elements** (location, date, user-marked changes, optional symptom notes) interact with the **HERA taxonomy** and introduce **new or amplified risks**. I’ll ask targeted reflection questions, surface concrete risks with their **HERA dimension IDs**, and suggest **actionable mitigations** referencing relevant **regulations**.

---

### **HERA Dimension: [P2.D3] — Data Collection and Use**  
**Reflection Question:** *How does the app handle the collection of location data (e.g., GPS coordinates) and user-marked changes, and does it align with GDPR and MDR requirements?*

**Concrete Risk:**  
- **Location data** (e.g., GPS coordinates) is considered **special category data** under GDPR and may require **explicit consent** and **purpose limitation**.  
- **User-marked changes** could be interpreted as **health-related data**, which is also **special category data** under GDPR.  
- **Symptom notes** may contain **health-related information**, which could fall under **Article 9** of GDPR.

**Regulatory Reference:**  
- **GDPR Article 9** (special category data)  
- **GDPR Article 6** (lawful basis for processing)  
- **MDR Article 10** (risk management for medical devices)

**Actionable Mitigation:**  
- **Obtain explicit consent** for the collection of location data and health-related data.  
- **Limit the purpose** of data collection to what is strictly necessary for the app’s functionality (e.g., tracking changes over time).  
- **Anonymize or pseudonymize** location data where possible.  
- **Store symptom notes securely**, ensuring they are encrypted and access-controlled.  
- **Include a privacy notice** that clearly explains how each type of data is used, stored, and shared.

---

### **HERA Dimension: [P2.D1] — Data Minimization**  
**Reflection Question:** *Does the app collect only the minimum necessary data to achieve its purpose, or does it collect more than needed (e.g., location, symptom notes)?*

**Concrete Risk:**  
- Collecting **location data** and **symptom notes** may be **more than necessary** for the app’s core purpose (i.e., tracking mole changes over time). This could increase the **risk of data misuse** or **breach**.

**Regulatory Reference:**  
- **GDPR Article 5(1)(c)** (data minimization)  
- **MDR Article 10** (risk management)

**Actionable Mitigation:**  
- **Audit the data collected** to ensure it aligns with the **core purpose** of the app.  
- **Offer users the option to disable** location tracking or symptom note input.  
- **Avoid collecting unnecessary data** unless it is essential for the app’s functionality or required by law.  
- **Document the data minimization rationale** in your **data processing activities record** (GDPR Article 30).

---

### **HERA Dimension: [P4.D6] — Transparency and User Control**  
**Reflection Question:** *Does the app clearly explain to users what data is collected (e.g., location, symptom notes), how it is used, and what rights users have over their data?*

**Concrete Risk:**  
- If users are not clearly informed about the **collection of location data** or **symptom notes**, they may not be able to **opt out** or **delete** their data, violating **GDPR Article 13** and **Article 14**.

**Regulatory Reference:**  
- **GDPR Article 13** (information to be provided to data subjects)  
- **GDPR Article 14** (data subject rights, including right to access and erasure)  
- **MDR Article 10** (user rights and transparency)

**Actionable Mitigation:**  
- **Clearly disclose** all data types collected (e.g., mole images, location, symptom notes) and their **purpose**.  
- **Provide users with a clear privacy notice** and **opt-out options**.  
- **Allow users to delete their data** at any time, including **location data** and **symptom notes**.  
- **Include a user-friendly interface** for managing data preferences and privacy settings.

---

### **HERA Dimension: [P5.D1] — Security and Data Protection**  
**Reflection Question:** *What security measures are in place to protect location data, symptom notes, and mole images from unauthorized access or breaches?*

**Concrete Risk:**  
- **Location data** and **symptom notes** are **sensitive** and could be exploited if not properly secured. A breach could lead to **privacy violations**, **identity theft**, or **misuse of health data**.

**Regulatory Reference:**

### USER
Mole photos (with location, date), user-marked changes, optional symptom notes.

### ASSISTANT
Thank you for the additional details. Let’s now explore how these **additional data elements** (location, date, user-marked changes, optional symptom notes) interact with the **HERA taxonomy** and introduce **new or amplified risks**. I’ll ask targeted reflection questions, surface concrete risks with their **HERA dimension IDs**, and suggest **actionable mitigations** referencing relevant **regulations**.

---

### **HERA Dimension: [P2.D3] — Data Collection and Use**  
**Reflection Question:** *How does the app handle the collection of location data (e.g., GPS coordinates) and user-marked changes, and does it align with GDPR and MDR requirements?*

**Concrete Risk:**  
- **Location data** (e.g., GPS coordinates) is considered **special category data** under GDPR and may require **explicit consent** and **purpose limitation**.  
- **User-marked changes** could be interpreted as **health-related data**, which is also **special category data** under GDPR.  
- **Symptom notes** may contain **health-related information**, which could fall under **Article 9** of GDPR.

**Regulatory Reference:**  
- **GDPR Article 9** (special category data)  
- **GDPR Article 6** (lawful basis for processing)  
- **MDR Article 10** (risk management for medical devices)

**Actionable Mitigation:**  
- **Obtain explicit consent** for the collection of location data and health-related data.  
- **Limit the purpose** of data collection to what is strictly necessary for the app’s functionality (e.g., tracking changes over time).  
- **Anonymize or pseudonymize** location data where possible.  
- **Store symptom notes securely**, ensuring they are encrypted and access-controlled.  
- **Include a privacy notice** that clearly explains how each type of data is used, stored, and shared.

---

### **HERA Dimension: [P2.D1] — Data Minimization**  
**Reflection Question:** *Does the app collect only the minimum necessary data to achieve its purpose, or does it collect more than needed (e.g., location, symptom notes)?*

**Concrete Risk:**  
- Collecting **location data** and **symptom notes** may be **more than necessary** for the app’s core purpose (i.e., tracking mole changes over time). This could increase the **risk of data misuse** or **breach**.

**Regulatory Reference:**  
- **GDPR Article 5(1)(c)** (data minimization)  
- **MDR Article 10** (risk management)

**Actionable Mitigation:**  
- **Audit the data collected** to ensure it aligns with the **core purpose** of the app.  
- **Offer users the option to disable** location tracking or symptom note input.  
- **Avoid collecting unnecessary data** unless it is essential for the app’s functionality or required by law.  
- **Document the data minimization rationale** in your **data processing activities record** (GDPR Article 30).

---

### **HERA Dimension: [P4.D6] — Transparency and User Control**  
**Reflection Question:** *Does the app clearly explain to users what data is collected (e.g., location, symptom notes), how it is used, and what rights users have over their data?*

**Concrete Risk:**  
- If users are not clearly informed about the **collection of location data** or **symptom notes**, they may not be able to **opt out** or **delete** their data, violating **GDPR Article 13** and **Article 14**.

**Regulatory Reference:**  
- **GDPR Article 13** (information to be provided to data subjects)  
- **GDPR Article 14** (data subject rights, including right to access and erasure)  
- **MDR Article 10** (user rights and transparency)

**Actionable Mitigation:**  
- **Clearly disclose** all data types collected (e.g., mole images, location, symptom notes) and their **purpose**.  
- **Provide users with a clear privacy notice** and **opt-out options**.  
- **Allow users to delete their data** at any time, including **location data** and **symptom notes**.  
- **Include a user-friendly interface** for managing data preferences and privacy settings.

---

### **HERA Dimension: [P5.D1] — Security and Data Protection**  
**Reflection Question:** *What security measures are in place to protect location data, symptom notes, and mole images from unauthorized access or breaches?*

**Concrete Risk:**  
- **Location data** and **symptom notes** are **sensitive** and could be exploited if not properly secured. A breach could lead to **privacy violations**, **identity theft**, or **misuse of health data**.

**Regulatory Reference:**

### USER
Mole photos (with location, date), user-marked changes, optional symptom notes.

### ASSISTANT
Thank you for the additional details. Let’s continue exploring the **HERA taxonomy** and how the **additional data elements** (location, date, user-marked changes, optional symptom notes) interact with the **regulatory and ethical landscape** in the **EU market**. I’ll focus on **HERA Dimension [P5.D1] — Security and Data Protection**, and then move to **[P7.D4] — Ethical Use and Harm Prevention**, and **[P4.D1] — User Consent and Control**.

---

### **HERA Dimension: [P5.D1] — Security and Data Protection**  
**Reflection Question:** *What security measures are in place to protect location data, symptom notes, and mole images from unauthorized access or breaches?*

**Concrete Risk:**  
- **Mole images** and **symptom notes** are **sensitive health data**, which are **special category data** under GDPR.  
- **Location data** (e.g., GPS coordinates) is also **sensitive** and may be used to infer **personal behavior** or **location patterns**, increasing the **risk of re-identification**.  
- A **breach** of this data could lead to **privacy violations**, **identity theft**, or **misuse of health information**.

**Regulatory Reference:**  
- **GDPR Article 32** (security of processing)  
- **GDPR Article 33** (notification of data breaches)  
- **EU AI Act, Article 5(2)** (data security requirements for high-risk systems)  
- **MDR Article 10** (risk management for medical devices)

**Actionable Mitigation:**  
- **Encrypt all data** at rest and in transit using strong encryption protocols (e.g., AES-256).  
- **Implement access controls** and **role-based permissions** to ensure only authorized personnel can access sensitive data.  
- **Conduct regular security audits** and **penetration testing** to identify and address vulnerabilities.  
- **Maintain a data breach response plan** and ensure that data breaches are reported within **72 hours** under GDPR Article 33.  
- **Consider ISO 27001** for a structured approach to information security management.  
- **Anonymize or pseudonymize** data where possible, especially location data and symptom notes.

---

### **HERA Dimension: [P7.D4] — Ethical Use and Harm Prevention**  
**Reflection Question:** *Is the app designed to prevent harm, such as false reassurance or unnecessary medical appointments, and does it avoid creating undue anxiety in users?*

**Concrete Risk:**  
- The app may lead to **false positives** (e.g., suggesting a dermatologist visit when there is no real risk), which could cause **unnecessary anxiety** or **strain on healthcare systems**.  
- Conversely, **false negatives** (not detecting changes when they exist) could lead to **delayed treatment** or **missed diagnoses**.  
- **Symptom notes** could be misinterpreted or used inappropriately, leading to **misdiagnosis** or **miscommunication** with healthcare providers.

**Regulatory Reference:**  
- **EU AI Act, Article 5(2)** (risk minimization)  
- **MDR Article 10** (risk management)  
- **GDPR Article 17** (right to erasure) and **Article 18** (right to object)

**Actionable Mitigation:**  
- Ensure that the app’s **thresholds for suggesting a dermatologist visit** are based on **clinical guidelines** and validated through **clinical testing**.  
- Include **disclaimers** and **warnings** to prevent users from relying solely on the app for medical advice.  
- Provide **clear instructions** on how to interpret user-marked changes and symptom notes.  
- Allow users to **opt out of automated recommendations** or **modify their inputs** to avoid misinterpretation.  
- **Document all decisions** and **user inputs** to ensure transparency and accountability in case of errors or harm.

---

### **HERA Dimension: [P4.D1] — User Consent and Control**  
**Reflection Question:** *Does the app ensure that users have full control over their data, including the ability to consent, withdraw consent, and delete their data?*

**Concrete Risk:**  
- Users may not be fully aware of how their **location data**, **symptom notes**, and **mole images** are being used, stored, or shared.  
- The app may not provide **clear and granular consent options**, leading to **lack of user control** over their data.  
- **Data minimization** may not be enforced, leading to **over-collection** of unnecessary data.

**Regulatory Reference:**  
- **GDPR Article 6** (lawful basis for processing)  
- **GDPR Article 

### USER
Mole photos (with location, date), user-marked changes, optional symptom notes.

### ASSISTANT
Thank you for the additional details. Let’s continue exploring the **HERA taxonomy** and how the **additional data elements** (location, date, user-marked changes, optional symptom notes) interact with the **regulatory and ethical landscape** in the **EU market**. I’ll focus on **HERA Dimension [P4.D1] — User Consent and Control**, and then move to **[P7.D4] — Ethical Use and Harm Prevention**, and **[P5.D1] — Security and Data Protection**.

---

### **HERA Dimension: [P4.D1] — User Consent and Control**  
**Reflection Question:** *Does the app ensure that users have full control over their data, including the ability to consent, withdraw consent, and delete their data?*

**Concrete Risk:**  
- **Location data** and **symptom notes** are **special category data** under GDPR, which requires **explicit consent** and **user control**.  
- If the app does not provide **granular consent options**, users may not be able to **opt out** of specific data types (e.g., location tracking, symptom notes).  
- The app may not allow users to **delete their data** or **export it**, which violates **GDPR Article 17** (right to erasure) and **Article 18** (right to object).

**Regulatory Reference:**  
- **GDPR Article 6** (lawful basis for processing)  
- **GDPR Article 13** (information to be provided to data subjects)  
- **GDPR Article 14** (data subject rights, including right to access and erasure)  
- **GDPR Article 17** (right to erasure)  
- **MDR Article 10** (user rights and transparency)

**Actionable Mitigation:**  
- **Provide clear and granular consent options**, allowing users to **opt in/out** of specific data types (e.g., location, symptom notes, mole images).  
- **Include a privacy notice** that clearly explains **what data is collected**, **how it is used**, and **what rights users have**.  
- **Allow users to delete their data** at any time, including **location data**, **symptom notes**, and **mole images**.  
- **Offer an export feature** for users to download their data in a structured format (e.g., CSV, PDF).  
- **Document all user consent choices** and **data deletion requests** in your **data processing activities record** (GDPR Article 30).

---

### **HERA Dimension: [P7.D4] — Ethical Use and Harm Prevention**  
**Reflection Question:** *Is the app designed to prevent harm, such as false reassurance or unnecessary medical appointments, and does it avoid creating undue anxiety in users?*

**Concrete Risk:**  
- The app may lead to **false positives** (e.g., suggesting a dermatologist visit when there is no real risk), which could cause **unnecessary anxiety** or **strain on healthcare systems**.  
- Conversely, **false negatives** (not detecting changes when they exist) could lead to **delayed treatment** or **missed diagnoses**.  
- **Symptom notes** could be misinterpreted or used inappropriately, leading to **misdiagnosis** or **miscommunication** with healthcare providers.

**Regulatory Reference:**  
- **EU AI Act, Article 5(2)** (risk minimization)  
- **MDR Article 10** (risk management)  
- **GDPR Article 17** (right to erasure) and **Article 18** (right to object)

**Actionable Mitigation:**  
- Ensure that the app’s **thresholds for suggesting a dermatologist visit** are based on **clinical guidelines** and validated through **clinical testing**.  
- Include **disclaimers** and **warnings** to prevent users from relying solely on the app for medical advice.  
- Provide **clear instructions** on how to interpret user-marked changes and symptom notes.  
- Allow users to **opt out of automated recommendations** or **modify their inputs** to avoid misinterpretation.  
- **Document all decisions** and **user inputs** to ensure transparency and accountability in case of errors or harm.

---

### **HERA Dimension: [P5.D1] — Security and Data Protection**  
**Reflection Question:** *What security measures are in place to protect location data, symptom notes, and mole images from unauthorized access or breaches?*

**Concrete Risk:**  
- **Mole images** and **symptom notes** are **sensitive health data**, which are **special category data** under GDPR.  
- **Location data** (e.g., GPS coordinates) is also **sensitive** and may be used to infer **personal behavior** or **location patterns**, increasing the **risk of

### USER
Delete account → everything wiped within 7 days.

### ASSISTANT
Thank you for the clarification. The **"Delete account → everything wiped within 7 days"** functionality introduces specific **regulatory and ethical risks** under the **HERA taxonomy**, particularly in the areas of **data erasure**, **user control**, and **security**. Let’s explore this in detail, using the **HERA taxonomy** and referencing relevant **regulations** such as **GDPR**, **MDR**, and the **EU AI Act**.

---

### **HERA Dimension: [P4.D1] — User Consent and Control**  
**Reflection Question:** *Does the app allow users to delete their data (including mole photos, location data, symptom notes) in a timely and complete manner, and does it align with GDPR and MDR requirements?*

**Concrete Risk:**  
- **Delayed data erasure** (within 7 days) may not meet the **GDPR requirement** for **immediate deletion** when users request it.  
- The **7-day delay** could expose data to **unauthorized access**, **data breaches**, or **misuse** during that window.  
- If the app does not provide **granular deletion options**, users may not be able to **delete specific data types** (e.g., only mole photos, not symptom notes), violating **user control**.

**Regulatory Reference:**  
- **GDPR Article 17** (Right to Erasure / Right to be Forgotten)  
- **GDPR Article 18** (Right to Object)  
- **MDR Article 10** (User rights and transparency)  
- **EU AI Act, Article 5(2)** (Data minimization and erasure)

**Actionable Mitigation:**  
- **Allow users to delete data immediately** (i.e., "delete now") rather than waiting 7 days.  
- **Provide granular deletion options**, enabling users to delete specific data types (e.g., mole photos, symptom notes, location data).  
- **Document all deletion requests** and **track the erasure process** in your **data processing activities record** (GDPR Article 30).  
- **Ensure that deleted data is irreversibly erased** (e.g., using secure deletion methods) to prevent recovery.

---

### **HERA Dimension: [P5.D1] — Security and Data Protection**  
**Reflection Question:** *What security measures are in place to protect user data during the 7-day delay before deletion, and how does this align with GDPR and MDR requirements?*

**Concrete Risk:**  
- Data stored for **7 days** is **exposed to potential breaches**, **unauthorized access**, or **data leaks**, increasing the **risk of privacy violations**.  
- **Location data** and **mole images** are **sensitive** and could be exploited if not properly secured during this period.  
- The **7-day delay** may not be **justified** if the app does not have a **clear legal basis** for retaining data temporarily.

**Regulatory Reference:**  
- **GDPR Article 30** (Record of processing activities)  
- **GDPR Article 32** (Security of processing)  
- **GDPR Article 33** (Notification of data breaches)  
- **EU AI Act, Article 5(2)** (Data minimization and security)  
- **MDR Article 10** (Risk management for medical devices)

**Actionable Mitigation:**  
- **Limit the retention period** to the **minimum necessary** (e.g., 24–48 hours instead of 7 days).  
- **Encrypt all data** during the 7-day delay, and ensure that **access controls** are strictly enforced.  
- **Conduct regular security audits** to ensure that data is not exposed to unauthorized access during the delay.  
- **Document the rationale** for the 7-day delay in your **data processing activities record** (GDPR Article 30).  
- **Notify users** of the **data retention period** and the **security measures** in place during that time.

---

### **HERA Dimension: [P7.D4] — Ethical Use and Harm Prevention**  
**Reflection Question:** *Does the 7-day delay in data erasure pose a risk of **undue exposure** of sensitive data (e.g., mole images, location data), and how can this be mitigated?*

**Concrete Risk:**  
- The **7-day delay** increases the **risk of data exposure**, which could lead to **privacy violations**, **stalking**, or **misuse** of sensitive health information.  
- **Location data** could be used to **track users** or **identify individuals**, especially if combined with **mole images**.  
- The **delay** may not be **justified** from an **ethical standpoint**, as users may expect **immediate erasure** of their data

### USER
Mole photos (with location, date), user-marked changes, optional symptom notes.

### USER
Thanks for the conversation. Could you produce a brief structured risk report now? Use HERA dimension IDs (e.g. [P1.D2]) and group risks by severity. End the report with a list of dimensions you didn't get to cover.

### ASSISTANT
**HERA Risk & Safety Risk Report**  
*For mHealth app with mole photos (with location, date), user-marked changes, optional symptom notes*

---

### **1. High Severity Risks**  
**[P5.D1] Security and Data Protection**  
- **Risk:** Sensitive health data (mole images, symptom notes) and location data are vulnerable to breaches, especially during deletion delays.  
- **Mitigation:** Implement strong encryption, access controls, and secure deletion methods.  
- **Regulation:** GDPR Article 32, EU AI Act Article 5(2), MDR Article 10.

**[P4.D1] User Consent and Control**  
- **Risk:** Users may not have full control over data types or deletion timelines (e.g., 7-day delay).  
- **Mitigation:** Allow granular consent and immediate deletion options.  
- **Regulation:** GDPR Article 17, MDR Article 10.

**[P7.D4] Ethical Use and Harm Prevention**  
- **Risk:** False positives/negatives in mole tracking could lead to unnecessary medical appointments or missed diagnoses.  
- **Mitigation:** Base recommendations on clinical guidelines and include clear disclaimers.  
- **Regulation:** EU AI Act Article 5(2), MDR Article 10.

---

### **2. Medium Severity Risks**  
**[P5.D2] Data Minimization and Retention**  
- **Risk:** Retaining data for 7 days may exceed necessary retention periods.  
- **Mitigation:** Justify and limit data retention to the minimum necessary.  
- **Regulation:** GDPR Article 5(1), MDR Article 10.

**[P4.D2] Transparency and Information**  
- **Risk:** Users may not be fully informed about how their data is used, especially location and symptom notes.  
- **Mitigation:** Provide clear, accessible privacy notices and data usage policies.  
- **Regulation:** GDPR Article 13, MDR Article 10.

**[P7.D3] Fairness and Non-Discrimination**  
- **Risk:** Location data could be misused for discriminatory purposes (e.g., tracking behavior).  
- **Mitigation:** Avoid using location data for non-medical purposes and ensure transparency.  
- **Regulation:** EU AI Act Article 5(2), GDPR Article 22.

---

### **3. Low Severity Risks**  
**[P3.D1] System Reliability and Performance**  
- **Risk:** App may fail to upload or store mole images, leading to data loss.  
- **Mitigation:** Implement robust data storage and backup mechanisms.  
- **Regulation:** MDR Article 10, ISO 82304-2.

**[P2.D4] Human Oversight and Accountability**  
- **Risk:** Lack of human oversight in interpreting user-marked changes could lead to misdiagnosis.  
- **Mitigation:** Ensure that critical decisions involve human review or consultation.  
- **Regulation:** EU AI Act Article 5(2), MDR Article 10.

---

### **Dimensions Not Covered in This Report**  
The following HERA dimensions were not addressed in this report and should be considered for a full risk assessment:  
- **[P1.D1] Purpose and Intent**  
- **[P1.D3] Transparency and Explainability**  
- **[P2.D1] Data Governance and Management**  
- **[P2.D2] Data Quality and Accuracy**  
- **[P3.D2] Interoperability and Integration**  
- **[P6.D1] User Empowerment and Control**  
- **[P6.D2] Accessibility and Inclusion**  
- **[P6.D3] Support and Assistance**  

---

**Next Steps:**  
- Conduct a full HERA assessment covering all dimensions.  
- Engage legal and compliance experts to align with GDPR, MDR, and EU AI Act.  
- Implement security, transparency, and user control measures to mitigate identified risks.

Now produce the JSON judgement object.